CEL-SCI is dedicated to improving the treatment of cancer and other diseases by unleashing the power of the immune system; the body's natural and most potent defense system. Our flagship product, MultikineŽ, is the first immunotherapeutic agent being developed as a first-line standard of care treatment for head and neck cancer.
Keywords: Biotechnology, cancer